A 47-year-old woman waits until the last five minutes of her appointment to mention that she has not had any interest in sex for almost two years. Her primary care doctor put her on an SSRI for what was labeled anxiety, her gynecologist told her vaginal dryness was "just menopause," and nobody has ever drawn a testosterone level on her. She apologizes for bringing it up. She tells me her husband is patient but she is not patient with herself. She asks if there is anything that actually works.
This is the conversation I have constantly in my practice, and it almost always comes at the end of the visit because patients have learned that the medical system does not have room for it. Female sexual dysfunction is one of the most undertreated conditions I see in mid-life women, and it is undertreated because the contributors are spread across hormonal, vascular, neurological, pharmacological, and psychological domains, and most clinicians are trained in only one of those. The patient ends up with a partial workup and a partial answer, and she stops asking.
In my practice the conversation does not get pushed to the last five minutes, and the workup is not partial.
What is actually going on physiologically
Sexual response in women is the integration of three systems: hormonal signaling that drives desire and tissue health, vascular response that drives arousal and engorgement, and central nervous system processing that translates a stimulus into a felt experience. All three have to work, and they have to work together. A meaningful problem in any one of them produces a meaningful clinical symptom.
Hormonal contributors. Testosterone is the primary driver of sexual desire in women, and it declines progressively from the late 30s onward. By the time a woman is 50, her free testosterone is often a fraction of what it was at 30. Estrogen maintains the integrity of vaginal and clitoral tissue — the epithelium thins without it, blood flow to the tissue decreases, and what was previously pleasurable becomes neutral or uncomfortable. Progesterone affects mood, sleep, and the sense of being settled in your body. Thyroid dysfunction, often subtle, suppresses libido and energy independent of the sex hormones.
Vascular contributors. Arousal is a vascular event. Engorgement of the clitoral and vulvar tissue requires intact endothelial function and adequate blood flow. The same vascular changes that produce early cardiovascular disease — endothelial dysfunction, atherosclerotic change in small vessels, blood pressure dysregulation — produce arousal difficulty before they produce a cardiac event. I take vascular complaints in this domain seriously because of what I saw in the cath lab. Genitourinary symptoms are sometimes the first vascular symptom a woman presents with.
Pharmacological contributors. SSRIs, SNRIs, beta-blockers, oral contraceptives, antihistamines, and PPIs all suppress sexual function as a side effect. SSRIs are the worst offender — they suppress desire, blunt arousal, and delay or prevent orgasm in a substantial percentage of patients who take them. Many of these patients were prescribed the SSRI for symptoms that were themselves driven by hormonal change, which means a hormonal workup was the right starting point and never happened.
Psychological and relational contributors. These are real and they matter, but they are usually not the entire story. A woman whose hormones, vascular function, and medications are addressed often finds that what looked like a relationship problem was a physiology problem the relationship was carrying.
How I evaluate someone for female sexual dysfunction
The first visit is a conversation, not a procedure. I block the time, the room is private, and I ask questions that the patient has often never been asked directly. When did the symptom start? Is the issue desire, arousal, lubrication, sensation, orgasm, pain, or some combination? What changed in the months before the symptom appeared — stressors, medications, hormonal events, postpartum, surgical menopause? What have you tried, and what happened?
Then I order labs. The panel I run for female sexual dysfunction includes total and free testosterone, SHBG, estradiol, progesterone, FSH, LH, DHEA-S, full thyroid panel including free T3 and T4, fasting insulin and HbA1c, a lipid panel, ferritin, and vitamin D. SHBG matters because elevated SHBG (often driven by oral contraceptives or thyroid changes) binds free testosterone and lowers what is bioavailable, even when total testosterone looks acceptable on paper. Free testosterone under 1.5 pg/mL in a symptomatic mid-life woman is a finding I treat. The conventional reference range for free testosterone in women extends low enough to call almost any deficient woman "normal."
I also review the medication list carefully. If an SSRI is in the picture, that conversation gets connected back to the prescribing provider, because sometimes the right move is a different antidepressant class, sometimes it is a dose reduction, and sometimes it is addressing the hormonal driver of the original symptom and tapering off the SSRI entirely.
The treatments that actually work
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
When the workup identifies a hormonal contributor, hormone optimization is foundational. Testosterone restoration in women — at physiologic doses, lab-monitored — improves desire, energy, mood, and tissue response. Estrogen supplementation, systemic or local depending on the picture, restores vaginal tissue health and reduces the discomfort that suppresses willingness to engage. Progesterone supports sleep and mood, which are themselves contributors to desire. Thyroid correction, when indicated, often produces a faster shift than patients expect.
For tissue-quality and arousal symptoms that persist after the hormones are addressed, the O-Shot is the regenerative tool I use. The mechanism is platelet-derived growth factor signaling injected into the clitoral and anterior vaginal tissue. The growth factors stimulate angiogenesis, collagen remodeling, and nerve sensitization in the treated tissue. The clinical effect develops over 8 to 12 weeks and is most noticeable in patients whose hormonal foundation is already addressed. Doing the O-Shot in a hormone-deficient patient gives a partial result. Doing it in a hormonally optimized patient gives the result the procedure is capable of.
For male partners — because this is often a couple-level conversation — men's hormone therapy and ED treatment are the parallel tools. A meaningful number of women I evaluate are dealing with their own physiology and their partner's at the same time, and addressing both produces a different outcome than addressing one.
What I tell patients to expect
The shifts are usually gradual. Two to four weeks after starting hormone optimization, sleep and mood often shift first. By 6 to 8 weeks, desire and energy follow. By 3 months, the picture is clear enough to refine the dose. Tissue-level changes from estrogen and from O-Shot work develop over 8 to 12 weeks. The patients who do best are the ones who give the protocol the full reassessment cycle and who address adjacent contributors in parallel rather than in sequence.
I also tell patients what I will not do. I do not put a woman on a fad supplement stack. I do not chase symptoms without a mechanism. I do not promise a single intervention will fix a multifactorial problem. The honest version of this work takes a comprehensive workup, an actual treatment plan, and a willingness to follow the data at each reassessment.
What the procedure itself looks like
For patients who are appropriate candidates for the O-Shot, the visit takes about 45 minutes from start to finish. We draw a small volume of blood from your arm and process it in a centrifuge to separate and concentrate the platelet layer, which carries the growth factors that drive the regenerative response. While the centrifuge runs, the treatment area is prepared with topical anesthetic. Once the PRP is ready, the injection itself is brief and is done with very fine needles into the anterior vaginal wall and the periclitoral tissue. Most patients describe pressure rather than sharp discomfort. Some report mild soreness for 24 to 48 hours afterward, comparable to the day after a long bike ride. You can return to normal activity the same day. Sexual activity is fine after 24 hours.
The protocol I use combines the O-Shot with hormonal optimization timed appropriately. Doing the O-Shot in a hormonally deficient patient is a partial intervention. Doing it after the estradiol, testosterone, and thyroid are addressed gives the procedure the foundation it needs to produce the full result.
The conversation about expectations
I want patients to know what is realistic and what is not. The O-Shot does not turn a 50-year-old's tissue and arousal response into a 25-year-old's. It can return a meaningful percentage of what has been lost, often enough to restore a satisfying experience that had become difficult or absent. For the patient whose symptoms are primarily hormonal, hormone optimization alone may produce the bulk of the response and the O-Shot may be unnecessary. For the patient whose symptoms are primarily vascular or tissue-quality based, hormone optimization alone is incomplete and the O-Shot adds something the medication cannot.
I also tell patients that the response to the first treatment is the data we use to plan the second. Some patients get most of the benefit from a single O-Shot and need only periodic maintenance every 12 to 18 months. Others benefit from a second treatment at 8 to 12 weeks to extend or deepen the initial response. The plan is built on what the body actually does, not on a fixed protocol that ignores individual variation.
Your concrete next step
If you have been holding off on this conversation, the next step is a 60-minute private intake visit with full lab work ordered at the end. Bring your medication list, including supplements and any hormonal contraception. Bring any prior labs you have, even if they are several years old — trends matter. The first visit is the conversation and the lab order; the second visit, two to three weeks later, is the lab review and the treatment plan. Book a private consultation at the Columbus consultation office or in Warner Robins. The consultation is private, the focus is on actually solving the problem, and the clinical protocols at both locations are the same.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.